GlassScriptPhysician profile
Thamer Sartawi
NPI 1639540669
$25,441.80
in general payments reported to CMS, 2019-2025
25 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $70.58 · 2021: $774 · 2022: $7,925 · 2023: $2,056 · 2024: $14K · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $1,405 · Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,000.00 |
| Travel and Lodging | $1,404.65 |
| Food and Beverage | $1,267.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $21,751.95 | 2022-2025 | Da Vinci Surgical System |
| Noah Medical Corporation | $1,678.85 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $468.19 | 2021-2023 | Breztri, Symbicort |
| Pulmonx Corporation | $369.67 | 2021-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.54 | 2021-2024 | Ofev |
| Jazz Pharmaceuticals INC. | $172.51 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $135.18 | 2020-2024 | Opsumit, Uptravi |
| Beigene USA, INC. | $125.00 | 2022 | |
| Ethicon INC. | $123.37 | 2021 | |
| Glaxosmithkline, LLC. | $91.83 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Insmed, INC. | $34.27 | 2021-2025 | Brinsupri |
| Janssen Pharmaceuticals, INC | $26.55 | 2021 | |
| Electromed, INC. | $23.68 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.31 | 2021 | |
| Mylan Specialty L.P. | $19.08 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.10 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $17.54 | 2024 | Dupixent |
| Gilead Sciences, INC. | $17.18 | 2021 | |
| Genentech USA, INC. | $16.75 | 2023 | Tecentriq |
| Takeda Pharmaceuticals U.S.A., INC. | $16.41 | 2022 | |
| Inspire Medical Systems, INC. | $16.09 | 2025 | Inspire |
| Grifols USA, LLC | $15.50 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.90 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $12.35 | 2021 | |
| Erbe USA INC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thamer Sartawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.